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Vascular endothelial growth factor (VEGF) expression is elevated in a wide variety of solid tumours. Inhibition of VEGF activities is
able to reduce angiogenesis and tumour growth. We have recently shown in vitro that carboxymethyl dextran benzylamide (CMDB7)
prevents the binding of VEGF165 to its cell surface receptors and thus inhibits VEGF activities on endothelial cells. In the present study,
we explored the effects of CMDB7 on highly aggressive human epidermoid carcinoma A431 cells known to overexpress epidermal
growth factor receptors (EGFRs) and produce a high amount of VEGF and a minor quantity of bFGF. In vitro, CMDB7 blocked the
mitogenic activity of A431-conditioned medium on endothelial cells. Concerning A431 cells, CMDB7 inhibited their proliferation and
the VEGF165 binding to them. In vivo, administration of CMDB7 (10mgkg
 1) three times per week for 2 weeks inhibited the growth
of A431 xenografts in nude mice by 73% as compared to the control group. Immunostaining of endothelial cells with mouse-specific
GSL-1 lectin in tumour sections revealed that CMDB7 also inhibited the density of intratumour endothelial cells by 66%. These
findings demonstrate that CMDB7 has an efficient antiangiogenic and antitumour action in vivo even when tumour cells produce a
high level of VEGF and EGFRs.
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Neovascularisation is critical for supporting the rapid growth of
solid tumours (Folkman, 1990). Tumour angiogenesis appears to
be achieved by the overexpression of angiogenic agents within
solid tumours that stimulate host vascular endothelial cell
mitogenesis and possibly chemotaxis. It is well established now
that the induction of vascular endothelial growth factor (VEGF)
expression, including via tumour hypoxia (Hlatky et al, 1994),
plays a major role in tumour angiogenesis (Dvorak et al, 1991;
Millauer et al, 1994; Goldman et al, 1998). In recent years, it has
been widely shown that VEGF activity is a key feature during
tumour growth and angiogenesis, and that blocking of this signal
transduction pathway may inhibit tumour progression (Cheng
et al, 1996; Relf et al, 1997). In vivo, VEGFs act as potent mitogenic
factors for endothelial cells and as blood vessel permeabilising
agents (Senger et al, 1983; Ploue ¨t et al, 1989; Klagsbrun and Soker,
1993; Yuan et al, 1996). The VEGF gene family currently includes
six members: VEGF-A (prototype VEGF), placenta growth factor
(PlGF), VEGF-B, VEGF-C, VEGF-D and VEGF-E, (produced by Orf
virus), (reviewed by Veikkola et al, 2000). VEGF is a homodimeric
glycoprotein that exists in six isoforms containing 121, 145, 162,
165, 189 and 206 amino-acid residues as a result of alternative
splicing from a single gene (Ferrara and Davis-Smith, 1997; Lange
et al, 2003). The predominant and the best characterised VEGF
species is the heparin-binding 165-amino acid-long form VEGF165
(reviewed by Neufeld et al, 1999).
Three receptors with tyrosine kinase activities have been
identified as VEGF receptors: VEGFR-1 (Flt-1) (deVries et al,
1992), VEGFR-2 (KDR/Flk-1) (Terman et al, 1992), proteins with
apparent molecular weights of 180 and 230kDa, respectively, and
VEGFR-3 (Kaipainen et al, 1995). They have been shown to bind
VEGF with high affinity. Recently, an additional binding site,
neuropilin-1 (NP-1), was identified and shown to be expressed on
the surface of endothelial and tumour cells (Soker et al, 1998). NP-
1 modulates the binding of VEGF165 to VEGFR-2 acting as a
coreceptor that enhances VEGF165-induced activities mediated by
VEGFR-2 (Whitaker et al, 2001; Soker et al, 2002).
Carboxymethyl dextran benzylamide (CMDB7) is a noncyto-
toxic substituted dextran. We have recently shown in vitro that it
prevents the binding of VEGF165 to human umbilical vein
endothelial cell surface and thus inhibits VEGF165-induced
phosphorylation of VEGFR-2 and consequently endothelial cell
proliferation (Hamma-Kourbali et al, 2001). In the present study,
we explored in vitro and in vivo the effects of CMDB7 on human
epidermoid carcinoma A431 cells known to produce a high
amount of VEGF and a minor quantity of bFGF (Myoken et al,
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s1991). The other peculiarity of A431 cells is the production of a
newly identified splice form of VEGF, VEGF-162, which binds
more efficiently than VEGF-165 to a natural basement membrane
of endothelial cells (Lange et al, 2003). Moreover, A431 cells
express a high level of epidermal growth factor receptors (EGFRs)
activated by EGF, a nonheparin-binding growth factor, which does
not interact with CMDB7 (Bagheri-Yarmand et al, 1998b).
Interestingly, the resistance of A431 tumours to treatment with
EGF receptor-blocking antibodies is associated with an elevated
expression of VEGF (Viloria-Petit et al, 2001). Such cells,
xenografted in nude mice, provide a model of highly VEGF-
dependent (Melnyk et al, 1996) and aggressive tumour growth in
an in vivo system. Since A431 cells have been recently described to
express the VEGF165-binding sites (Li et al, 2001), we explored also
the possible effect of CMDB7 on radiolabelled VEGF binding. We
demonstrate that CMDB7 acts on both tumour and endothelial
cells, decreasing in a potent manner the tumour growth and
angiogenesis in vivo.
MATERIALS AND METHODS
Dextran derivative preparation
A water-soluble dextran derivative (CMDB7) was prepared as
previously described (Chaubet et al, 1995). Its chemical composi-
tion, determined by acidimetric titration and elementary analysis
of nitrogen, is 0% dextran, 70% carboxymethyl and 30%
benzylamide. Average molecular weight was estimated as
80000gmol
 1.
Cell lines and cell culture
Human epidermoid carcinoma cell line (A431) and human
umbilical vein endothelial cell line (HUV-EC-C) were purchased
from the American Type Culture Collection (ATCC, Rockville, MD,
USA). A431 cells were routinely grown in DMEM (Life Technol-
ogies, Inc., Gaithersburg, MD, USA) and HUV-EC-Cs in M199 (Life
Technologies, Inc.) and were cultured at 371C in a 5% CO2-
humidified atmosphere. Both culture media were supplemented
with 10% foetal calf serum (FCS), 2mML -glutamine, 1mM sodium
pyruvate, 50Uml
 1 penicillin and 50mgml
 1 streptomycin (all
obtained from Life Technologies, Inc.). The cells were free of
mycoplasma, bacteria and viruses.
Preparation of conditioned media (CMs)
To assess the production of VEGF-A, the A431 cells at three
different density were seeded into a 24-well culture plate (Falcon,
Strasbourg, France) in DMEM supplemented with 10% FCS for
24h. To obtain CM containing only the growth factors secreted by
A431, the cells were washed twice with PBS, and incubated in 1ml
of serum-free DMEM containing 0.1% BSA (Sigma, St Louis, MO,
USA). At the indicated time, the media were collected, cleared by
centrifugation, and stored at  801C before use. For other
experiments, the cells were grown in 150mm-diameter Petri
dishes (Falcon) to 80% confluence in DMEM/10% FCS, washed and
incubated in 10mldish
 1 of serum-free medium.
Determination of VEGF-A concentration in the A431-CMs
by radioimmunoassay
The surface of flat-bottomed polystyrene wells (Disposable
Immulon 1 Remowawell, Dynatech, Cambridge, MA, USA) were
coated overnight at 41C with 200ml of PBS buffer containing 50ng
polyclonal neutralising anti-VEGF IgG (R&D Systems, Abingdon,
UK). The nonspecific interactions were saturated with PBS
containing 0.1% BSA and 0.01% Tween-20 (PBT buffer) for an
additional overnight at 41C. After blocking, the wells were washed
three times with 300ml of PBT buffer. Then, A431-CM or VEGF165
(R&D Systems) as standard at increasing concentrations (0–
250ngml
 1) and 50pM
125I-VEGF165 (Amersham Pharmacia
Biotech, Orsay, France) were added to a final volume of 200mli n
PBT buffer. After an overnight incubation at 41C, wells were
washed three times with 300ml of PBT buffer and the radioactivity
remaining in each well was measured in a g-counter (LKB 1261
Multigamma).
A431-CM effects on HUV-EC-C proliferation
HUV-EC-Cs were seeded at a density of 2 10
4well
 1 into 24-well
tissue culture plates (Falcon) in M199-10% FCS. After 24h, the
cells were growth arrested by serum starvation for another 24h.
Then, the cells were incubated for 48h with A431-CM diluted in a
serum-free medium to a final VEGF concentration of 10ngml
 1
(concentration at which VEGF165 has the maximal mitogenic effect
on HUV-EC-Cs (Hamma-Kourbali et al, 2001) in the presence or
absence of 5mM CMDB7 (optimal concentration at which CMDB7
completely prevents the VEGF165 mitogenic effect on HUV-EC-Cs
(Hamma-Kourbali et al, 2001) or 1mgml
 1 anti-human VEGF
neutralising antibody (Sigma) characterised by neutralisation
dose50¼0.01–0.1mgml
 1. Cells were washed with PBS, dissociated
with 0.025% trypsin-EDTA (Life Technologies) and counted using
a Coulter counter (Coultronics, Margency, France). All experi-
ments were performed in triplicate and data illustrate the mean cell
numbers7s.e. provided from one representative of three inde-
pendent experiments.
A431 proliferation assay
A431 cells were seeded at a density of 10
4 cellswell
 1 into 24-well
tissue culture plates (Falcon) in DMEM–10% FCS and allowed to
adhere to the plastic for 24h. After washing with DMEM, the cells
were incubated with CMDB7 at the indicated concentrations (day
zero) in DMEM–1% FCS. At different times, cells were washed
with PBS, dissociated with 0.025% trypsin-EDTA (Life Technolo-
gies, Inc.) and counted using a Coulter counter (Coultronics). In
each case, samples were performed in triplicate, and data illustrate
mean cell numbers7s.e. of one representative of three indepen-
dently performed experiments.
VEGF165 binding to A431 cells
For displacement binding assays, A431 cells were grown until
confluence on 24-well tissue culture plates (Falcon). After an
overnight incubation in serum-free medium and two washings
with ice-cold binding buffer (PBS/0.1% BSA), the cells were
incubated with 7pM
125I-VEGF165 (Amersham, Pharmacia Biotech)
and CMDB7 at various concentrations from 8 10
 9 to 4 10
5 M
at 41C for 2h. Incubation was terminated by gently aspirating the
medium and washing the cell monolayer three times with ice-cold
binding buffer. After cell solubilisation in 0.3ml of 0.5 N NaOH, the
bound radioactivity was measured in a g-counter (LKB 1261
Multigamma). Nonspecific binding was determined in the
presence of an excess (5000pM) of unlabelled VEGF165 (R&D
Systems).
Tumour cell inoculation in nude mice
All in vivo experiments were carried out with ethical committee
approval and met the standards required by the UKCCCR
guidelines (Workman et al, 1998). A431 cells (5 10
6) were
inoculated s.c. in the right flank of 4-week-old athymic nude mice
(nu/nu) (Charles River Laboratory, Aubin-les-Elbeuf, France). The
animals (n¼20) were kept in a temperature-controlled room on a
12h:12h light–dark schedule with food and water ad libitum. All
mice developed single s.c. palpable tumours of approximately
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s50mm
3 6 days after cell inoculation. Then, mice were placed in
control (n¼10) and CMDB7-treated groups (n¼10). Mice were
treated by subcutaneous (s.c.) injection of 0.1ml PBS alone
(control) or containing 10mgkg
 1 CMDB7 close to the tumour,
three times a week for 2 weeks. Tumours were measured along two
major axes with a calliper. Tumour volume was calculated as
follows:
V ¼ð 4=3ÞpR2
1R2;
where R1 is radius 1, R2 is radius 2, and R1 oR2.
Tissue preparation and immunohistochemical staining
Immediately after surgical resection, the tumour specimens were
fixed with 4% paraformaldehyde and processed to paraffin
inclusion. The intratumour mice endothelial cells were specifically
stained with GSL-1 lectin (Vector Laboratories, Burlingame, CA,
USA) in 5-mm sections as previously described (Bagheri-Yarmand
et al, 1999). The GSL-1 lectin binds specifically to galactosyl
residues present on vascular endothelium in mice (Alroy et al,
1987; Mattsson et al, 2002). The proliferative index of tumour
xenograft was determined by human Ki-67 staining with mono-
clonal mouse antibody (MIB-1; 1:50; Dako, Trappes, France). The
epitope retrieval was performed in 10mM citrate buffer pH¼6.0
for 40min at 981C. Specific reactions were visualised with 3,30-
diaminobenzidine (DAB) as chromogen.
Image analysis
For each GSL-1- or MIB-1-labelled section of control or CMDB7-
treated tumour, five fields containing exclusively viable tumour
cells, as indicated by the haematoxylin staining, were selected
randomly for analysis. Image analysis was performed using the
NIH programme (developed at NIH and available on the Internet
at http://rsb.info.nih.gov/nih-image/). The endothelial cell density
in each field was expressed as the ratio of endothelial cell area and
the total viewed area  100 (%). To determine the proliferative
index, we estimated the percentage of tumour cell nuclei positive
for Ki-67 marker. These values were then averaged for untreated
(control) and treated-CMDB7 tumours.
Statistical analysis
Multiple statistical comparisons were performed using ANOVA in
a multivariate linear model. Statistical comparisons were con-
ducted using the Mann–Whitney t-test. Po0.05 was considered
statistically significant.
RESULTS
CMDB7 inhibits, like neutralising anti-VEGF165 antibody,
mitogenic effect of A431-CM on HUV-EC-Cs
According to previous studies (Melnyk et al, 1996), we found that
A431 cells secrete in the culture medium large amounts of VEGF-
A. Moreover, we showed here that VEGF production is cell
number- and time-dependent (Table 1).
As expected, A431-CM stimulated the in vitro proliferation of
HUV-EC-Cs by 2.5-fold after 48h of incubation (Figure 1). This
mitogenic effect is, at least in part, VEGF-specific since the
neutralising antibodies against recombinant VEGF inhibited the
A431-CM-induced proliferation of HUV-EC-Cs by 45% after 48h
treatment. A431-CM, used in this experiment, contained
10ngml
 1 of VEGF165 as revealed by specific radioimmunoassay.
At the same concentration, recombinant VEGF165 has a similar
mitogenic effect on HUV-EC-Cs (Hamma-Kourbali et al, 2001), as
described above the addition of 5mM CMDB7 prevented the
stimulatory effect of A431-CM on HUV-EC proliferation (Figure 1).
When HUV-EC-Cs were cultivated in serum-free medium, CMDB7
or neutralising anti-VEGF165 antibodies had no effect.
CMDB7 inhibits A431 cell proliferation in vitro
Next, we tested CMDB7 for its ability to affect the in vitro growth
of A431 tumour cells. We demonstrated that treatment with
CMDB7 at increasing concentrations, ranging from 0.1 to 20mM,
resulted in a concentration- and time-dependent inhibition of
A431 cell number (Figure 2).
In contrast, 1mgml
 1 anti-VEGF antibody had no effect on A431
proliferation in vitro (data not shown) as reported by others
(Melnyk et al, 1996).
CMDB7 inhibits VEGF165 binding to A431 tumour cells
Since A431 cells produce VEGF-A and binds VEGF165 on the
surface (Li et al, 2001), we explored if CMDB7 is able to compete
for VEGF165-specific binding (Figure 3). CMDB7 decreased the
125I-VEGF165-specific binding to A431 cells at concentrations
ranging from 0.1 to 50mM with a half-maximum inhibitory effect
(IC50) at concentration 2mM.
Table 1 Concentration of VEGF in the conditioned media of A431
tumour cells
Cell number 24h 48h
2.5 10
4 o0.4 1
5 10
4 24
10
5 81 6
A431 cells were seeded at the indicated density into 24-well plate in DMEM–10%
FCS medium for 24h. After washing, they were incubated in serum-free medium. At
the indicated time, the media were collected. VEGF-A concentration was asessed by
radio immunoassay as described in Materials and Methods. Values are in ngml
 1.T h e
limit of sensitivity of the assay was 0.4ngml
 1.
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Figure 1 CMDB7 inhibits A431-CM mitogenic effect. Quiescent HUV-
EC cells were incubated with A431-CM with or without 5mM CMDB7 or
1mgml
 1 anti-human VEGF neutralising antibody. After 48h, the cells were
trypsinised and counted using a Coulter counter. The values represent
mean cell numbers7s.e. (bars), obtained in triplicate in one of the three
independent experiments.
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sCMDB7 inhibits the growth of A431 cells xenografted in
nude mice
The tumours appeared in 100% of mice 6 days after A431 cell
inoculation. CMDB7 inhibited the growth of A431 tumours by 73%
(Po0.001) after 2 weeks of treatment (Figure 4).
No apparent toxicity was noticed during treatment with CMDB7.
No signs of toxicity such as diarrhoea, infection, weakness or
lethargy were observed. The body weight of the inoculated mice
was not affected by CMDB7 after 2 weeks of treatment. All treated
mice were alive at the end of treatment.
CMDB7 decreases the proliferative index of A431
xenografts
The specific Ki-67 staining was less intense in CMDB7-treated
tumours as compared to control (nontreated) ones. The prolif-
erative index for treated and control xenografts were significantly
(P¼0.05) diffferent, 2678 and 34710%, respectively (mean7
s.e.m). These data suggest that CMDB7 inhibited directly in vivo
the proliferation of tumour cells. In all xenografts, treated as well
as nontreated, the areas of necrosis/apoptosis were large, but
localised in the centre of tumour. There did not appear to be
obvious differences in the degree of necrosis observed in both
cases. We had no difficulties in obtaining five fields of viable cells
in all tumours.
CMDB7 inhibits the intratumour endothelial cell density
Selective GSL-1 staining showed that CMDB7 treatment reduced
the endothelial cell quantity in tumour tissue (Figure 5B) as
compared to control (Figure 5A). The mean percentage of
endothelial cell area (endothelial cell density) in viable fields of
CMDB7-treated tumours (2.9 7 0.6; 50 fields in 10 tumours) was
inhibited by 66% (Po0.001) as compared to control tumour value
(8.670.7; 50 fields in 10 tumours) (Figure 5C).
DISCUSSION
Antiangiogenesis is a promising therapeutic approach for the
treatment of cancer (Folkman, 1995; Schweigerer, 1995). VEGF
plays a crucial role in tumour angiogenesis and the inhibition of
VEGF action decreases tumour growth in vivo (Kim et al, 1993;
Goldman et al, 1998; Lin et al, 1998). Since the human A431
carcinoma cells secrete high amounts of VEGF (Myoken et al,
1991) and develop in nude mice tumours whose growth is highly
VEGF-dependent (Melnyk et al, 1996), they provide a good model
to test the availability of molecules that inhibit VEGF bioactivity.
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Figure 2 Inhibition of A431 cell growth in vitro. A431 cells were seeded
at 10
4 cellswell
 1 in 24-well plates in DMEM containing 10% FCS. On the
following day (day 0), the medium was changed to DMEM containing 1%
serum (x) and 0.1mM (J), 1mM (K), 5mM (&), 10mM (’), 15mM (n), or
20mM (m) CMDB7. At the indicated time, cells were trypsinised and
counted. The inset shows the percentages of inhibition of the A431 cell
growth by CMDB7 at increasing concentrations at day 6. The values
represent mean cell numbers7s.e. (bars), obtained in triplicate in one of
the three independent experiments.
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Figure 3 CMDB7 inhibits VEGF165 binding to A431 cells. Confluent
A431 cells were incubated for 2h at 41C in the presence of 7pM
125I-
VEGF165 and CMDB7 at the indicated concentrations (logarithmic scale).
Nonspecific binding was determined in the presence of 5000pM unlabelled
VEGF165. Results are expressed as the mean7s.e. (bars) of experiments
done in duplicates and repeated at least twice.
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Figure 4 CMDB7 inhibits primary tumour growth. A431 carcinoma cells
(5 10
6) were inoculated s.c. into the right flank of female nude mice.
When tumour volume reached 100mm
3 (6 day), CMDB7 (10mgkg
 1)
was administrated s.c. three times a week for 2 weeks. Tumours were
measured and the results are presented as the mean tumour volume 7s.e.
(bars) obtained from 10 mice in each group, Po0.001; CMDB7-treated
group vs controls.
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described recently in vitro (Hamma-Kourbali et al, 2001), on A431
xenografted in nude mice, an extremely aggressive tumour model.
CMDB7 is, to our knowledge, the only one of heparin analogues
reported to be efficient in A431 xenograft model.
This study demonstrated that the s.c. injection of viable A431
cells yielded a 100% tumour uptake rate. The 2 week treatment
with CMDB7 resulted in a 73% tumour growth inhibition
associated with a 66% decrease in endothelial cell density.
Compared to the human breast MDA-MB-435 (Bagheri-Yarmand
et al, 1999) and MCF-7ras (Bagheri-Yarmand et al, 1998b)
tumours, the magnitude of response of the A431 tumours to
CMDB7 treatment was greater. Here, we observed that rapid A431
tumour growth was associated with high intratumour endothelial
cell density, suggesting a direct relation between vascularisation
within the primary tumour and the tumour growth rate. In 3-week-
old A431 control (untreated) tumours, the endothelial cell density
was 8.6%, while in 12-week-old MDA-MB-435 and MCF-7ras
xenografts this value was 4.9% (Bagheri-Yarmand et al, 1999) and
6.1% (Bagheri-Yarmand et al, 1998b), respectively. Our observa-
tions are in agreement with results of Kim (1993), which
demonstrated that the inhibitory effect of anti-VEGF antibody on
tumour growth was more pronounced in the case of human A673
rhabdomyosarcoma secreting the highest quantity of VEGF and
giving the most rapidly growing tumours as compared to G55
glioblastoma and SK-LMS-myosarcoma. In the CMDB7-treated
tumours, a reduction of 66% in the density of endothelial cells
indicates that this treatment attenuated the rate of neovascularisa-
tion, but did not completely reverse the initial activation of
angiogenesis. The augmentation of CMDB7 dose did not result in
increased efficiency of the drug in vivo (data not shown). Our
results demonstrate that CMDB7 inhibited A431 tumour growth
by, at least in part, decreasing intratumour endothelial cell density.
The mechanism of CMDB7 action on endothelial cells is probably
not direct and involves, as we recently described in vitro (Hamma-
kourbali et al, 2001), a direct interaction of the drug with VEGF165
that becomes unavailable for specific receptors. In agreement, we
demonstrate here that CMDB7 inhibits the A431-CM stimulation
of endothelial cell proliferation.
The other mechanism by which CMDB7 reduced the A431
tumour growth is direct inhibition of A431 cell proliferation as
evidenced by a decrease of proliferative index in treated xenografts
compared to nontreated ones. In this study, we demonstrated that
CMDB7 inhibited, like VEGF, the binding of
125I-VEGF165 to A431
cells with IC50 similar to the concentration at which CMDB7
inhibits efficiently the A431 proliferation in vitro. These findings
could argue for the possible autocrine mitogenic action of VEGF
on A431 cells. However, the depletion of VEGF amount in A431-
conditioned medium by anti-VEGF antibody did not affect the
A431 proliferation, although it did inhibit endothelial cell growth.
It suggests that VEGF binding sites on the A431 cell surface are not
involved in classical, KDR-dependent transmission of mitogenic
signal. The A431 growth decrease by CMDB7 in vitro could involve
the inhibition of other mitogenic growth factors. This interpreta-
tion can be strengthened by our previous studies demonstrating
that CMDB7 inhibited the activity of heparin-binding PDGF and
TGFb by altering their conformation, but did not change the
activity of EGF and IGF1, which are not heparin-binding growth
factors (Bagheri-Yarmand et al, 1997, 1998a,b). Independently, the
possible VEGF autocrine pathway in A431 could mediate tumour
cell survival by protecting them from apoptosis as it was recently
reported for breast cancer MDA-MB-231 cells (Bachelder et al,
2001). Further studies are necessary to understand the mechanisms
of direct CMDB7 inhibitory action on A431 proliferation in vitro.
Altogether, our findings demonstrate that CMDB7 has a strong
antiangiogenic and antitumour action in vivo, also when tumour
cells produce a high level VEGF and EGFRs. CMDB7 acts directly
on both tumour and endothelial cells, decreasing in a potent
manner the tumour growth by increasing the proliferation of
tumour cells and especially angiogenesis in vivo. The development
of resistance to antiangiogenic drugs is becoming apparent (Kerbel
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Figure 5 CMDB7 inhibits the tumour angiogenesis. Intratumour
vascularisation was analysed immunohistologically after labelling of
endothelial cells with a specific marker GSL-1. (A) Section of saline-
treated (control) tumour and (B) section of tumour treated with
30mgkgweek
 1 of CMDB7. (C) Endothelial cell density was evaluated
by image analysis of GSL-1-labelled endothelial cells and the results are
presented as the mean areas7s.e. (bars) of endothelial cells in the
CMDB7-treated and control tumour sections obtained from 10 mice for
each group. **, significantly different from control (Po0.001).
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set al, 2001). It is very important, now, to enlarge the diversity of
molecular targets for antiangiogenic drugs and to use a combina-
tion of antiangiogenic therapies. One of the possible mechanisms
of this resistance may be due to redundancy of different
proangiogenic growth factors made by tumour cells. When one
angiogenic factor is targeted, the cancer cells increase production
of other angiogenic factors. In this context, we believe that the
ability of CMDB7 to interact with several angiogenic factors,
including VEGF (Hamma-Kourbali et al, 2001), bFGF (Bagheri-
Yarmand et al, 1997, 1998a), TGF-b and PDGF (Bagheri-Yarmand
et al, 1998b), will permit to oppose or at least put off the
development of resistance. Recently, it was reported that the
resistance of tumours to treatment with EGF receptor-blocking
antibodies can be associated with an elevated expression of VEGF
(Viloria-Petit et al, 2001). Since we show in this study that CMDB-7
efficiently blocks in vivo the effects of VEGF produced at high
level, we can speculate that this drug could be useful in the case of
failure to anti-EGFR treatment. It is believed now that because
angiogenesis is a complex and multistage process, treatment with
more than one antiangiogenic agent may be beneficial (Cherring-
ton et al, 2000). Also, the neutralisation of angiogenic growth
factors, especially VEGF, in tumour with CMDB7 may increase the
effects of a variety of antiangiogenic inhibitors (Kerbel et al,
2001). For example, the reduced ability of Taxotere to induce
apoptosis of endothelial cells in the presence of VEGF (Sweeney
et al, 2001) could be restored by combined treatment with
CMDB7. CMDB7 can be used not only as monotherapy but also
especially in combination with other antiangiogenic and
anticancer drugs to cause acute tumour regression by delaying
development of resistance and by enhancing the effects of
other drugs.
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